Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 26431-26440 Newer>

The Motley Fool October 2, 2007 Lawrence A. Rothman	Can the Right Prescription Heal Walgreen? Walgreen is suffering from heightened competition, expenses rising more than 11%, and the company itself predicting its challenges will probably continue into the near future.
The Motley Fool October 2, 2007 Seth Jayson	eBay's Partial Failure eBay hits shareholders with an impairment charge of $900 million for its Skype purchase, more than a third of the original cash and stock price.
The Motley Fool October 2, 2007 Steven Mallas	Disney and The Rock: A Great Tag Team The new Disney family film The Game Plan offers further proof that Disney's branding strategy works. Disney wants to focus on family fare and keep its movie slate to a minimum number of releases that yield a maximum return.
The Motley Fool October 2, 2007 Charly Travers	Too Early for Timberland The company lowers its Q3 guidance and announces that it will shut down 40 of its specialty retail stores. Investors, this may be a turnaround company waiting for its turnaround.
The Motley Fool October 2, 2007 Tim Beyers	Who's Filing Now? Late Filings: Avery Dennison settles a lawsuit regarding its Employee Savings Plan... Taleo corporation discloses that Gap, a Taleo customer, incurred data loss resulting from a stolen laptop... Nortel completes redemption of its senior notes... etc.
The Motley Fool October 2, 2007 Brian Orelli	PerkinElmer and ViaCell: A Bloody Good Deal? PerkinElmer buys umbilical cord storage company ViaCell for $300 million. Investors, take note; the merger may be a good fit for both companies.
The Motley Fool October 2, 2007 Tom Taulli	Acxiom of Shareholder Evil ValueAct Capital Partners said it plans to abandon its buyout of Acxiom, causing shares of the information-based product development company to tumble.
The Motley Fool October 2, 2007 Billy Fisher	Closure for Bristol-Myers Bristol-Myers will pay $515 million to resolve cases from state and federal authorities alleging that the company promoted products for uses that hadn't been approved by the FDA.
The Motley Fool October 2, 2007 Tim Beyers	Vive le iPhone Battle For all the hype concerning the iPhone, we investors ought to remember that Apple's iconic creation has yet to face its toughest battle. France is once again the battleground.
The Motley Fool October 2, 2007 Rich Smith	Foolish Forecast: Might Mechel Miss? The Russian coal and steel producer is set to report its second-quarter 2007 earnings. Investors, here is what you can expect to see.
<Older 26431-26440 Newer> Return to current articles.